Effect of zopiclone combined with Deanxit on cytokines and neurotransmitters in patients with poststroke depression

Objective: To explore the effect of zopiclone combined with Deanxit on cytokines and neurotransmitters in patients with poststroke depression. Methods: A total of 78 patients with poststroke depression who were treated in Zaozhuang Mining Group Dongjiao Hospital between January 2015 and February 2017 were divided into control group (n=41, receiving conventional Deanxit therapy) and zopiclone group (n=37, receiving zopiclone combined with Deanxit therapy). The differences in serum nerve injury marker, inflammatory cytokine and monoamine neurotransmitter levels were compared between the two groups before treatment and after 12 weeks of treatment. Results: Before treatment, serum levels of nerve injury markers, inflammatory cytokines and monoamine neurotransmitters were not significantly different between the two groups. After 12 weeks of treatment, serum nerve injury markers NSE and S100B levels of zopiclone group were lower than those of control group whereas BDNF level was higher than that of control group;serum inflammatory cytokines IL-1, IL-2, IL-23 and TNF-α levels of zopiclone group were lower than those of control group;serum monoamine neurotransmitters NE, 5-HT and DA levels of zopiclone group were higher than those of control group. Conclusion: Zopiclone combined with Deanxit therapy can effectively optimize the neurological function, reduce the inflammatory response and increase the secretion of monoamine neurotransmitters in patients with poststroke depression.